Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors
Authors
Keywords
Pruritus, Primary myelofibrosis, Treatment options, <em class=EmphasisTypeItalic >JAK</em> inhibitors
Journal
ANNALS OF HEMATOLOGY
Volume 95, Issue 7, Pages 1185-1189
Publisher
Springer Nature
Online
2016-04-23
DOI
10.1007/s00277-016-2674-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management
- (2015) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Essential Thrombocythemia: The Dermatologic Point of View
- (2015) Emanuele Cozzani et al. Clinical Lymphoma Myeloma & Leukemia
- Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors
- (2015) Ruben A. Mesa et al. LEUKEMIA & LYMPHOMA
- Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice
- (2015) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
- (2015) A Pardanani et al. Blood Cancer Journal
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management
- (2013) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Aquagenic pruritus in polycythemia vera: Characteristics and influence on quality of life in 441 patients
- (2013) Fabian P. Siegel et al. AMERICAN JOURNAL OF HEMATOLOGY
- Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management
- (2013) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- (2013) A Pardanani et al. LEUKEMIA
- Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management
- (2012) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
- (2012) S. Verstovsek et al. BLOOD
- The evolving treatment paradigm in myelofibrosis
- (2012) Ruben A. Mesa LEUKEMIA & LYMPHOMA
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pruritus in primary myelofibrosis: Clinical and laboratory correlates
- (2011) Brianna E. Vaa et al. AMERICAN JOURNAL OF HEMATOLOGY
- The Impact of Pruritus on Quality of Life
- (2011) Seema P. Kini ARCHIVES OF DERMATOLOGY
- Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
- (2011) R. Scherber et al. BLOOD
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients
- (2010) Alejandra Martínez-Trillos et al. ANNALS OF HEMATOLOGY
- Polycythemia vera-associated pruritus and its management
- (2010) Kamal S. Saini et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
- (2010) A Pardanani et al. LEUKEMIA
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
- (2009) Ruben A. Mesa et al. LEUKEMIA RESEARCH
- Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis
- (2008) Naseema Gangat et al. AMERICAN JOURNAL OF HEMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started